Gutiérrez-Cerrajero, Carlos http://orcid.org/0000-0002-9698-2920
Sprecher, Eli
Paller, Amy S.
Akiyama, Masashi http://orcid.org/0000-0001-5863-9315
Mazereeuw-Hautier, Juliette
Hernández-Martín, Angela http://orcid.org/0000-0001-7260-8718
González-Sarmiento, Rogelio http://orcid.org/0000-0002-2726-6795
Article History
Accepted: 2 December 2022
First Online: 19 January 2023
Competing interests
: The authors declare the following competing interests: A.S.P.: investigator for AbbVie, AnaptysBio, Eli Lilly, Incyte, Janssen, Krystal Biotech, Regeneron Pharmaceuticals Inc. and UCB; consultant with honorarium for AbbVie, Acrotech, Almirall, Amgen, Amryt Pharma, Arcutis Biotherapeutics, Arena Pharmaceuticals, Azitra, BioCryst, BiomX, BMS, BridgeBio, Castle Creek Biosciences, Catawba Research, Eli Lilly, Exicure, Gilead, Incyte, Janssen, Johnson & Johnson, Kamari Pharma, LEO Pharma, Novartis, OM Pharma, Pfizer, Pierre Fabre, RAPT Therapeutics, Regeneron Pharmaceuticals, Inc., Sanofi, Seanergy and UCB; data and safety monitoring board for AbbVie, Abeona Therapeutics, Bausch Health, Galderma and Novan. J.M.-H.: investigator for Sanofi, Mayne Pharma and Timber Pharmaceuticals. A.H.-M.: investigator for Mayne Pharma and Celgene. C.G.-C., E.S., M.A. and R.G.-S. declare no competing interests.